Log in

NASDAQ:CHMAChiasma Stock Price, Forecast & News

+0.08 (+1.70 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $4.79
50-Day Range
MA: $5.04
52-Week Range
Now: $4.79
Volume319,747 shs
Average Volume616,476 shs
Market Capitalization$202.43 million
P/E RatioN/A
Dividend YieldN/A
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Read More
Chiasma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.13 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CHMA



Sales & Book Value

Annual SalesN/A
Book Value$2.04 per share


Net Income$-36,320,000.00


Market Cap$202.43 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableNot Optionable
+0.08 (+1.70 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Chiasma (NASDAQ:CHMA) Frequently Asked Questions

How has Chiasma's stock been impacted by COVID-19 (Coronavirus)?

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CHMA stock has increased by 22.2% and is now trading at $4.79.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Chiasma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chiasma

When is Chiasma's next earnings date?

Chiasma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Chiasma

How can I listen to Chiasma's earnings call?

Chiasma will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05.
View Chiasma's earnings history

What price target have analysts set for CHMA?

3 Wall Street analysts have issued 1 year price targets for Chiasma's stock. Their forecasts range from $11.00 to $19.00. On average, they expect Chiasma's stock price to reach $16.00 in the next year. This suggests a possible upside of 234.0% from the stock's current price.
View analysts' price targets for Chiasma

Has Chiasma been receiving favorable news coverage?

Headlines about CHMA stock have trended very positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Chiasma earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Chiasma

Are investors shorting Chiasma?

Chiasma saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 1,830,000 shares, a drop of 15.7% from the July 15th total of 2,170,000 shares. Based on an average daily trading volume, of 752,200 shares, the days-to-cover ratio is presently 2.4 days. Approximately 4.6% of the company's shares are sold short.
View Chiasma's Current Options Chain

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

Who are Chiasma's key executives?

Chiasma's management team includes the following people:
  • Mr. Raj Kannan, CEO & Director (Age 56, Pay $475.78k)
  • Mr. Mark J. Fitzpatrick, Pres (Age 57, Pay $788.3k)
  • Mr. Lee Giguere, VP & Gen. Counsel (Age 40, Pay $134.52k)
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 55, Pay $520.92k)
  • Mr. Drew Enamait, VP of Fin. & Admin. (Age 46)

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Who are Chiasma's major shareholders?

Chiasma's stock is owned by a number of retail and institutional investors. Top institutional investors include Bessemer Group Inc. (0.13%), WINTON GROUP Ltd (0.13%), Virtu Financial LLC (0.09%), Trexquant Investment LP (0.07%), SG Americas Securities LLC (0.05%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam.
View institutional ownership trends for Chiasma

Which major investors are selling Chiasma stock?

CHMA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and WINTON GROUP Ltd.
View insider buying and selling activity for Chiasma

Which major investors are buying Chiasma stock?

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Virtu Financial LLC, Trexquant Investment LP, State Board of Administration of Florida Retirement System, ProShare Advisors LLC, and SG Americas Securities LLC. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Raj Kannan, Scott Minick, and William Ludlam.
View insider buying and selling activity for Chiasma

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $4.79.

How big of a company is Chiasma?

Chiasma has a market capitalization of $202.43 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

What is Chiasma's official website?

The official website for Chiasma is www.chiasmapharma.com.

How can I contact Chiasma?

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.